MK-6482 Shows Promise in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
The HIF-2a Inhibitor induced clinical responses among patients with von Hippel-Lindau disease–associated kidney cancer, according to results presented at the 2020 ASCO Virtual Scientific Program.